BlinkLab (ASX:BB1) added Drexel University as a clinical site for its pivotal US regulatory trial for its BlinkLab Dx 1 autism diagnostic test, according to a Thursday Australian bourse filing.
Drexel University became the ninth institution to participate in the FDA 510(k) registrational trial across the US. The study will enroll around 528 children, between the ages of 2 and 11 years.
Its shares fell 4% in recent trading on Thursday.